247 related articles for article (PubMed ID: 29505900)
41. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
Choi YJ; Lee DH; Choi CM; Lee JS; Lee SJ; Ahn JH; Kim SW
BMC Cancer; 2015 Oct; 15():763. PubMed ID: 26493267
[TBL] [Abstract][Full Text] [Related]
43. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
Socinski MA; Saleh MN; Trent DF; Dobbs TW; Zehngebot LM; Levine MA; Bordoni R; Stella PJ
Ann Oncol; 2009 Jun; 20(6):1068-73. PubMed ID: 19188136
[TBL] [Abstract][Full Text] [Related]
44. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Vokes EE; Herndon JE; Kelley MJ; Cicchetti MG; Ramnath N; Neill H; Atkins JN; Watson DM; Akerley W; Green MR;
J Clin Oncol; 2007 May; 25(13):1698-704. PubMed ID: 17404369
[TBL] [Abstract][Full Text] [Related]
45. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
[TBL] [Abstract][Full Text] [Related]
46. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
47. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F; Fenton D; Hirsh V; Zukin M; Stockler MR; Lee CW; Chen EX; Montenegro A; Ding K; Bradbury PA
Eur J Cancer; 2014 Mar; 50(4):706-12. PubMed ID: 24360368
[TBL] [Abstract][Full Text] [Related]
48. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
50. Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Ding T; Li ZT; Zhang X; Shi YT
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3723-3729. PubMed ID: 28925468
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
[TBL] [Abstract][Full Text] [Related]
52. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
53. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
54. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
55. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
56. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
57. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
Belani CP; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM
J Clin Oncol; 2003 Aug; 21(15):2933-9. PubMed ID: 12885812
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
59. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
60. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials.
Hamada C; Tsuboi M; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
J Thorac Oncol; 2009 Dec; 4(12):1511-6. PubMed ID: 19875974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
